BioScrip Inc. Spikes After Comments Made On CNBC (BIOS)

BioScrip Inc. (Nasdaq: BIOS) Spikes After Comments Made On CNBC (BIOS). Heartland Advisors Will Nasgovitz fund is up some 37% this year.

Nasgovitz said one of his main holdings is a small-cap, BioScrip Inc. BioScrip is up over 250% this year and Will Nasgovitz still thinks BioScrip has more room to run and BIOS will continue to be a main holding in the fund.

BioScrip moved up from $8 to $8.11 after Will talked about it on CNBC.

BioScrip is a pharma company that sells pharmaceuticals to individuals that have Hepatitis C or HIV and its business has been doing great. BioScrip has a new management team and their operating margin is expanding.

Nasgovitz thinks the valuation is still very compelling and BIOS it will remain a top 5 holding in their fund.


There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.

Post new comment

The content of this field is kept private and will not be shown publicly.